Disability Rating Scales in Parkinson's Disease: Critique and Recommendations

Shulman, Lisa M.; Armstrong, Melissa J.; Ellis, Terry; Gruber‐Baldini, Ann L.; Horak, Fay B.; Nieuwboer, Alice; Parashos, Sotirios A.; Post, Bart; Rogers, Mark W.; Siderowf, Andrew; Goetz, Christopher G.; Schrag, Anette; Stebbins, Glenn T.; Martinez‐Martín, Pablo

doi:10.1002/mds.26649

Cited by 97 publications

(59 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first part of Part I and Parts III and IV are evaluated by physicians, whereas the second part of Part I and the whole Part II are self-administered by patients. MDS-UPDRS can be used for different applications, but in some pharmacogenetic studies, where the efficacy of dopaminergic drugs is evaluated in association with genetic factors, the main efficacy criterion is a difference in MDS-UPDRS score over a particular period of time [16,[23][24][25][26]]. …”

Section: Treatment Efficacy Evaluation With the Mds-unified Parkinsonmentioning

confidence: 99%

Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease

Redenšek¹,

Trošt²,

Dolžan³

2018

Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies

View full text Add to dashboard Cite

Parkinson's disease (PD) is a chronic progressive neurodegenerative brain disorder presenting with motor signs and symptoms, such as akinesia, rest tremor, rigidity, and later in disease progression postural instability. However, nonmotor symptoms may harm patients' quality of life even more than the motor ones. The etiopathogenesis is not clear yet. PD may develop due to a combination of genetic and environmental factors. It is treated symptomatically with dopaminergic drugs. The gold standard of PD management is L-Dopa, however also other drugs are frequently used, such as dopamine agonists, MAOB inhibitors, COMT inhibitors, and occasionally amantadine and anticholinergic drugs. Many patients experience several adverse events of L-Dopa treatment, such as different motor complications. Furthermore, nonmotor adverse events of dopaminergic treatment may occur. The efficacy of drugs varies between patients as well. Several polymorphic genes have already been associated with treatment outcome in PD, such as metabolic enzymes, transport and receptor genes, and might serve as treatment outcome prediction factors. As gene-environment interactions were also shown to contribute to PD development, they might also be able to predict treatment response. Such genetic biomarkers could be helpful in personalized care of PD patients to prevent adverse events and inefficacy of a certain drug.

show abstract

Section: Treatment Efficacy Evaluation With the Mds-unified Parkinsonmentioning

confidence: 99%

Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease

Redenšek¹,

Trošt²,

Dolžan³

2018

Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies

View full text Add to dashboard Cite

show abstract

“…Timed Up and Go test (TUG) is one that can be applied in PD population [21]. TUG has been used to assess patients with moderate to severe PD [22].…”

Section: Introductionmentioning

confidence: 99%

“…Studies have revealed that instrumented TUG (iTUG) can provide more information comparing to measures taken by a classical TUG [15,21,22]. A major part of this research includes use of different types of camera based assessment tools for instrumental motion analysis [4,6].…”

Section: Introductionmentioning

confidence: 99%

Microsoft Kinect-based differences in lower limb kinematics during modified timed up and go test phases between men with and without Parkinson’s disease

Kähär

Taba

Nõmm

et al. 2018

AKUT

View full text Add to dashboard Cite

The aim of the study was to analyse with Microsoft Kinect (Kinect) the differences in lower limb kinematics during sub-phases of modified Timed Up and Go test (modTUG) in men with Parkinson's disease (PD) compared to healthy age-matched male individuals. Eight men with mild-to-moderate PD (age 67.5±4.5 yrs) and eight healthy men (age 69.8±8.0 yrs) participated. Kinect along with KinectPsyManager (v1.0) and Matlab2016b software was used for data collection. Selected lower limb kinematics and gait speed (GS) were calculated during sittingto-walking (STW) transition while performing modTUG. According to Kinect men with mild to moderate PD did not differ from healthy counterparts in aspects of postural characteristics of STW, with the exception of smaller distance between knees while sitting (p<0.001). Men with PD were found to perform the walking phase of STW transition slower (p<0.01) and with slower GS (p<0.01) comparing to healthy men. In conclusion, compared to healthy men, Kinect detects smaller distance between knees during sitting before transitioning from STW in men with mild to moderate PD. In addition, men with PD also demonstrated slower GS and a longer walking phase of STW transition in comparison to healthy men.

show abstract

“…The assessment can be based on observations of actual ADL performance, interviews, or self-ratings. Assessments can address difficulties in performing ADL, dependence on assistance from others and from assistive devices, or a combination of both [3]. Several ADL rating scales have been psychometrically tested and recommended for use with people with PD [3].…”

Section: Introductionmentioning

confidence: 99%

“…Assessments can address difficulties in performing ADL, dependence on assistance from others and from assistive devices, or a combination of both [3]. Several ADL rating scales have been psychometrically tested and recommended for use with people with PD [3]. These rating scales typically include around ten items and have been shown to be highly associated with walking difficulties ( r s 0.74–0.86) [4] and physical functioning ( r 0.63–0.77) [5, 6].…”

Section: Introductionmentioning

confidence: 99%

Psychometric Evaluation of the Parkinson’s Disease Activities of Daily Living Scale

Jonasson

Hagell

Hariz

et al. 2017

Parkinson's Disease

View full text Add to dashboard Cite

Objective To evaluate a set of psychometric properties (i.e., data completeness, targeting, and external construct validity) of the Parkinson's disease Activities of Daily Living Scale (PADLS) in people with Parkinson's disease (PD). Specific attention was paid to the association between PADLS and PD severity, according to the Hoehn & Yahr (H&Y) staging. Methods The sample included 251 persons with PD (mean age 70 [SD 9] years). Data collection comprised a self-administered postal survey, structured interviews, and clinical assessments at home visits. Results Data completeness was 99.6% and the mean PADLS score was 2.1. Floor and ceiling effects were 22% and 2%, respectively. PADLS scores were more strongly associated (rs > 0.5) with perceived functional independence, ADL dependency, walking difficulties, and self-rated PD severity than with variables such as PD duration and cognitive function (rs < 0.5). PADLS scores differed across H&Y stages (Kruskal-Wallis test, p < 0.001). Those in H&Y stages IV-V had more ADL disability than those in stage III (Mann–Whitney U test, p < 0.001), whereas there were no significant differences between the other stages. Conclusion PADLS revealed excellent data completeness, acceptable targeting, and external construct validity. It seems to be well suited as a rough estimate of ADL disability in people with PD.

show abstract

Disability Rating Scales in Parkinson's Disease: Critique and Recommendations

Cited by 97 publications

References 98 publications

Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease

Effects of Genetic Variability in Dopaminergic Pathway on Treatment Response in Parkinson’s Disease

Microsoft Kinect-based differences in lower limb kinematics during modified timed up and go test phases between men with and without Parkinson’s disease

Psychometric Evaluation of the Parkinson’s Disease Activities of Daily Living Scale

Contact Info

Product

Resources

About